Melphalan
- Generic Name
- Melphalan
- Brand Names
- Alkeran, Evomela, Phelinun, Pepaxti
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18Cl2N2O2
- CAS Number
- 148-82-3
- Unique Ingredient Identifier
- Q41OR9510P
- Background
Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is...
- Indication
Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.
...
- Associated Conditions
- Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)
- Conditions
- Interventions
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 51
- Registration Number
- NCT04682405
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults
- Conditions
- Refractory Malignant Peripheral Nerve Sheath TumorEwing Sarcoma/Peripheral Primitive Neuroectodermal TumorRecurrent NeuroblastomaRecurrent RhabdomyosarcomaRefractory Malignant Solid NeoplasmDesmoplastic Small Round Cell TumorRecurrent Malignant Peripheral Nerve Sheath TumorRefractory Desmoplastic Small Round Cell TumorRecurrent Desmoplastic Small Round Cell TumorRecurrent Malignant Solid Neoplasm
- Interventions
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT04530487
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT04521946
Personalized Autologous Transplant for Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2020-07-23
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Emory University
- Target Recruit Count
- 90
- Registration Number
- NCT04483206
- Locations
- 🇺🇸
University Illinois Chicago, Chicago, Illinois, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
Haplo Peripheral Blood Sct In GVHD Prevention
- First Posted Date
- 2020-07-16
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Zachariah Michael DeFilipp
- Target Recruit Count
- 25
- Registration Number
- NCT04473911
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2020-07-10
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT04466475
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
A Prospective International Multicenter Clinical Trial for Eyes With Relapsed Retinoblastoma
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Prof. Beck Popovic Maja
- Target Recruit Count
- 2
- Registration Number
- NCT04455139
- Locations
- 🇨🇭
CHUV Lausanne University Hospital, Lausanne, Switzerland
A PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM Patients
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2023-03-09
- Lead Sponsor
- Oncopeptides AB
- Target Recruit Count
- 27
- Registration Number
- NCT04412707
- Locations
- 🇺🇦
Public Non-Profit Enterprise "Kyiv City Clinical Hospital #9" under the Executive Body of Kyiv City Council, Hematology Department #1, Kyiv, Ukraine
🇨🇿University Hospital Olomouc, Clinic of Hemato-Oncology, Olomouc, Czechia
🇧🇬Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Sofia, Bulgaria
Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation
- Conditions
- Interventions
- First Posted Date
- 2020-05-20
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 21
- Registration Number
- NCT04395222
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis
- Conditions
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationDrug: BusulfanDrug: CyclophosphamideDrug: FludarabineDrug: MelphalanDrug: MethotrexateDrug: Mycophenolate MofetilDrug: RuxolitinibDrug: TacrolimusRadiation: Total-Body IrradiationProcedure: Computed TomographyProcedure: EchocardiographyProcedure: Bone Marrow Aspiration and BiopsyProcedure: Magnetic Resonance ImagingProcedure: Ultrasound Imaging
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT04384692
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.